Results 221 to 230 of about 247,609 (252)

Reducing unnecessary osteoporosis treatment in prostate cancer with FRAX‐BMD integration

open access: yesUroPrecision, EarlyView.
ABSTRACT Background Men on androgen deprivation therapy (ADT) for prostate cancer frequently develop osteoporosis, and up to 20% fracture within five years. The Fracture Risk Assessment Tool (FRAX) estimates 10‐year fracture probability with or without bone mineral density (BMD), but data in this population are scarce.
Takashi Kawahara   +10 more
wiley   +1 more source

Survival Benefit of ARSI Therapy in Japanese mCSPC: A Systematic Review and Meta-Analysis. [PDF]

open access: yesInt J Urol
Iwamoto H   +14 more
europepmc   +1 more source

Recent progress on the development of hydrogel‐based microneedles for transdermal drug delivery

open access: yesVIEW, EarlyView.
This study provides a comprehensive and up‐to‐date analysis of recent progress in HMN technology, covering fundamental transdermal delivery mechanisms and design principles, biomaterials used in HMN fabrication, drug loading and release strategies, and emerging therapeutic applications.
Mohammad Muhtasim Ittisaf   +5 more
wiley   +1 more source

Longitudinal [<sup>18</sup>F]FDG PET/MR Assessment of Arterial Inflammation in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy. [PDF]

open access: yesCirc Cardiovasc Imaging
Xue S   +10 more
europepmc   +1 more source

Correction: Spatial transcriptomics reveals Inhba/Smad2/E2f4 axis in Lrp2<sup>high</sup> thecal cell proliferation in androgen-induced PCOS mice. [PDF]

open access: yesFront Cell Dev Biol
Luo M   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy